Compare
Disc Medicine, Inc. vs Ocular Therapeutix, Inc vs Vireo Growth Inc. vs MannKind Corp
| Latest fiscal year | Disc Medicine, Inc. IRON | Ocular Therapeutix, Inc OCUL | Vireo Growth Inc. VREOF | MannKind Corp MNKD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $51.95M | $268.77M | $348.97M |
| Revenue growth (YoY) | n/a | -18.5% | +170.4% | +22.2% |
| Gross margin | n/a | 87.3% (computed) | 47.3% | 92.3% (computed) |
| Operating margin | n/a | -519.8% | -0.4% | 11.1% |
| Net margin | n/a | -511.9% | -25.3% | 1.7% |
| Net income | -$212.18M | -$265.94M | -$68.11M | $5.86M |
| EPS (Diluted) | -$6.01 | -$1.42 | -$0.09 | $0.02 |
| Operating cash flow | -$180.39M | -$204.88M | $3.71M | $18.25M |
| Free cash flow | -$181.33M | -$216.89M | -$24.61M | $13.69M |
| Cash & equivalents | $91.14M | $737.06M | n/a | $74.88M |
| Total assets | $806.88M | $808.06M | $817.15M | $792.18M |
| Total liabilities | $67.05M | $153.75M | $509.73M | $843.20M |
| Shareholders' equity | $739.83M | $654.31M | $307.42M | -$51.02M |
| Return on year-end equity | -28.7% | -40.6% | -22.2% | n/a |
| Shares outstanding | 37.89M | 215.93M | n/a | 307.83M |
Revenue, most recent five fiscal years
| Fiscal year | Disc Medicine, Inc. | Ocular Therapeutix, Inc | Vireo Growth Inc. | MannKind Corp |
|---|---|---|---|---|
| Latest | n/a | $51.95M Ended 2025-12-31 | $268.77M Ended 2025-12-31 | $348.97M Ended 2025-12-31 |
| 1 year earlier | n/a | $63.72M Ended 2024-12-31 | $99.38M Ended 2024-12-31 | $285.50M Ended 2024-12-31 |
| 2 years earlier | n/a | $58.44M Ended 2023-12-31 | $88.13M Ended 2023-12-31 | $198.96M Ended 2023-12-31 |
| 3 years earlier | n/a | $51.49M Ended 2022-12-31 | $74.63M Ended 2022-12-31 | $99.77M Ended 2022-12-31 |
| 4 years earlier | n/a | $43.52M Ended 2021-12-31 | $54.45M Ended 2021-12-31 | $75.44M Ended 2021-12-31 |